12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zytiga abiraterone acetate regulatory update

Johnson & Johnson submitted regulatory applications to FDA and EMA for Zytiga abiraterone acetate to treat chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or mildly asymptomatic after failing androgen deprivation...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >